Tibotec News
 22 July 2010 - TMC278 PIVOTAL PHASE 3 CLINICAL TRIALS ACHIEVE PRIMARY OBJECTIVE
Data on once-daily, treatment-naive use of TMC278, the third antiretroviral compound developed by Tibotec Pharmaceuticals, presented at International AIDS Conference
Read more...
15 April 2010 - MORE THAN HALF OF HCV GENOTYPE-1 PATIENTS WHO FAILED PRIOR THERAPY WITH STANDARD OF CARE ACHIEVE SUSTAINED VIRAL RESPONSE (SVR) WITH A TELAPREVIR-BASED REGIMEN
MORE THAN HALF OF HCV GENOTYPE-1 PATIENTS WHO FAILED PRIOR THERAPY WITH STANDARD OF CARE ACHIEVE SUSTAINED VIRAL RESPONSE (SVR) WITH A TELAPREVIR-BASED REGIMEN -- Phase 2 telaprevir data presented at EASL --
Read more...
08 April 2010 - TELAPREVIR-BASED REGIMENS MORE EFFECTIVE THAN STANDARD OF CARE IN CURING HCV GENOTYPE 1 PATIENTS WHO FAILED PREVIOUS THERAPY
TELAPREVIR-BASED REGIMENS MORE EFFECTIVE THAN STANDARD OF CARE IN CURING HCV GENOTYPE 1 PATIENTS WHO FAILED PREVIOUS THERAPY -- Phase 2 telaprevir study published in New England Journal of Medicine --
Read more...
25 November 2009 - U.S. Food and Drug Administration (FDA) Grants Traditional Approval for
INTELENCE® (Etravirine)
Read more...
12 November 2009 - Once Daily PREZISTA® (darunavir) Monotherapy Shows Similar Efficacy and Safety as Combination Therapy
48-week monotherapy data presented at the 2009 European AIDS Society Conference
Read more...
31 October 2009 - More than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response wtih Twice-Daily Telaprevir-Based Regimen
Phase II telaprevir data from Tibotec featured in oral presentation at AASLD
Read more...
21 July 2009 - Study Shows PREZISTA®-Based HIV Therapy May Improve Immune Cell Function in Treatment Experienced Patients
Data presented from GRACE immunology substudy
Read more...
20 July 2009 - New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies
GRACE compares efficacy and safety of PREZISTA/ritonavir in treatment-experienced women vs. men at 48 weeks
Read more...
20 July 2009 - 96-Week Safety and Efficacy Findings Presented for INTELENCE(TM)
(Etravirine) As Part of HIV Combination Therapy
Read more...
16 July 2009 - Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 And Truvada® With Gilead Sciences
Product Could Represent a New, Once-Daily Antiretroviral Treatment Option
Read more...
|
